Dr. Venkata K. Parsa
Claim this profileRegional Cancer Center-Lee Memorial Health System
Area of expertise
Lung Cancer
Venkata K. Parsa has run 3 trials for Lung Cancer. Some of their research focus areas include:
Non-Small Cell Lung Cancer
Venkata K. Parsa has run 2 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
Regional Cancer Center-Lee Memorial Health System
Clinical Trials Venkata K. Parsa is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting
2 awards
Phase 3
2 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
More about Venkata K. Parsa
Clinical Trial Related
3 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Venkata K. Parsa has experience with
- Gemcitabine Hydrochloride
- Carboplatin
- Paclitaxel
- Pembrolizumab
- Pemetrexed Disodium
- Biospecimen Collection
Breakdown of trials Venkata K. Parsa has run
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Venkata K. Parsa specialize in?
Venkata K. Parsa focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage II patients, or patients who are Stage III.
Is Venkata K. Parsa currently recruiting for clinical trials?
Yes, Venkata K. Parsa is currently recruiting for 4 clinical trials in Fort Myers Florida. If you're interested in participating, you should apply.
Are there any treatments that Venkata K. Parsa has studied deeply?
Yes, Venkata K. Parsa has studied treatments such as Gemcitabine Hydrochloride, Carboplatin, Paclitaxel.
What is the best way to schedule an appointment with Venkata K. Parsa?
Apply for one of the trials that Venkata K. Parsa is conducting.
What is the office address of Venkata K. Parsa?
The office of Venkata K. Parsa is located at: Regional Cancer Center-Lee Memorial Health System, Fort Myers, Florida 33905 United States. This is the address for their practice at the Regional Cancer Center-Lee Memorial Health System.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.